Cidara Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Davarpanah Nicole Negar unloaded Company’s shares for reported $29797.0 on Sep 11 ’25. In the deal valued at $62.86 per share,474 shares were sold. As a result of this transaction, Davarpanah Nicole Negar now holds 31,418 shares worth roughly $6.89 million.
Then, RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares, generating $99,999,988 in total proceeds. Upon buying the shares at $44.00, the Director now owns 3,365,523 shares.
Before that, Mineo Chrysa bought 2,270 shares. Cidara Therapeutics Inc shares valued at $49,281 were divested by the Director at a price of $21.71 per share. As a result of the transaction, Mineo Chrysa now holds 2,270 shares, worth roughly $0.5 million.
RBC Capital Mkts downgraded its Cidara Therapeutics Inc [CDTX] rating to a Sector perform from a an Outperform in a research note published recently A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in mid November from “an Overweight” to “an Equal-weight”. JP Morgan also remained covering CDTX and has decreased its forecast on November 17, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Morgan Stanley started covering the stock on October 16, 2025. It rated CDTX as “an Overweight”.
Price Performance Review of CDTX
On Friday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock fall -0.09% to $219.35. Over the last five days, the stock has gained 0.75%. Cidara Therapeutics Inc shares have risen nearly 1303.39% since the year began. Nevertheless, the stocks have risen 716.03% over the past one year. While a 52-week high of $220.41 was reached on 11/20/25, a 52-week low of $15.22 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 218.84, which if violated will result in even more drops to 218.33. On the upside, there is a resistance level at 219.88. A further resistance level may holdings at 220.41.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-10-31, growing by 0.16 million shares to a total of 3.2 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.05 million shares. There was a rise of 4.91%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 10, 2025 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $200 price target.
